by Korea University College of Medicine A new study finds that switching from long-term TDF to BSV may improve renal and bone safety, with no differences observed in the antiviral efficacy. Credit: Dr. Hyung Joon Yim from Korea University Ansan hospital Hepatitis B is a liver infection caused by the hepatitis B virus (HBV), and...
Tag: <span>hepatitis B</span>
Post
Researchers move closer to a functional cure for chronic hepatitis B
Reviewed Chinese Academy of SciencesMar 17 2025 Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma. Despite widespread vaccination and antiviral treatments, millions of people still suffer from chronic hepatitis B virus (HBV) infection. The primary challenge in curing the disease lies in the persistence of...
Post
Preventing Hepatitis B Reactivation: Updated Clinical Guidance From AGA
Diana Swift March 07, 2025 013 The American Gastroenterological Association (AGA) has released an updated clinical practice guideline on the prevention of hepatitis B virus reactivation (HBVr) in at-risk persons. The document was published in Gastroenterology and replaces a previous guideline on prophylaxis for immunosuppressed patients issued in 2014. Since then, many novel classes of immunosuppressives have been approved...
Post
Digging into a decades-old hepatitis B mystery suggests a new potential treatment
by Memorial Sloan Kettering Cancer Center Atomic force microscopy images show hepatitis B DNA in its natural state (left) and a zoomed-in look at how it wraps around human histones during an infection (right). The research team determined that in order for a critical protein to get made, the hepatitis B virus’s DNA needs to get...
Post
How stigma affects Asian Americans living with hepatitis B
August 28, 2024 by Marilyn Perkins, Thomas Jefferson University Credit: Pixabay/CC0 Public DomainAsian Americans comprise just 6% of the U.S. population, but they represent over 60% of Americans with hepatitis B. Hepatitis B (HBV) is a virus that infects the liver, and while some people may recover from the infection, others can go on to...
Post
Hepatitis B vaccine: What to know to protect yourself
by Mayo Clinic News Network, Mayo Clinic News Network Credit: CC0 Public DomainHepatitis is inflammation in the liver caused by specific viruses. The hepatitis viruses are referred to as types A, B, C, D and E. All types affect the liver, but they differ in illness severity and prevention options. In the U.S., the most...
Post
New tool to study hepatitis B could open the door to a cure
by Rockefeller University The RNA launch system. Credit: Science Advances (2023). DOI: 10.1126/sciadv.adg6265 Hepatitis C and hepatitis B viruses both attack the liver, eventually causing deadly cirrhosis or cancer. But while antivirals can cure 95% of HCV infections, its cousin HBV has long eluded effective therapeutics. As a result, nearly 1 million people die from HBV every year....
Post
Commonly used antiretroviral drugs used to treat HIV and hepatitis B reduce immune cells’ energy production
by University of California, Los Angeles The study included a complementary translational approach with both preclinical in vitro studies and clinical studies using accessible PBMCs from HIV-1(−) participants (men and women) and people with HIV (PWH) with suppressed plasma viremia on TAF-based versus TDF-based ART. Credit: Theodoros Kelesidis New UCLA-led research suggests that antiretroviral drugs called TAF...
Post
Researchers develop social media-based intervention to promote Hepatitis B screening among Korean Americans
by George Mason University Credit: Unsplash/CC0 Public Domain Hepatitis B virus (HBV) infection is the leading cause of cirrhosis and primary liver cancer, globally affecting nearly 300 million people. In the United States, Asian Americans account for 7% of the total population, but more than 50% of all HBV infections. Foreign-born Asian Americans face tremendous...
Post
New immunotherapy ‘highly effective’ against hepatitis B
by University College London Credit: CC0 Public Domain Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world. Each year, globally, chronic HBV causes an estimated 880,000 deaths from liver cirrhosis and hepatocellular carcinoma/liver cancer (HCC). The pioneering study used immune cells isolated...
- 1
- 2